These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24309125)

  • 1. Review of blood pressure control rates and outcomes.
    Bakris G; Sarafidis P; Agarwal R; Ruilope L
    J Am Soc Hypertens; 2014 Feb; 8(2):127-41. PubMed ID: 24309125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial.
    Sato A; Watanabe S; Okubo S; Toi T; Doi T; Nakano H; Tada J; Aonuma K;
    Hypertens Res; 2010 Dec; 33(12):1264-71. PubMed ID: 20927115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are fixed-dose combination antihypertensives suitable as first-line therapy?
    Kjeldsen SE; Messerli FH; Chiang CE; Meredith PA; Liu L
    Curr Med Res Opin; 2012 Oct; 28(10):1685-97. PubMed ID: 22978777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
    Chazova IE; Martynyuk TV
    Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving blood pressure control rates by optimizing combination antihypertensive therapy.
    Epstein BJ
    Expert Opin Pharmacother; 2010 Aug; 11(12):2011-26. PubMed ID: 20590485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes from treatment. Clinical applications from recent trials.
    Howes LG
    Aust Fam Physician; 1999 Jul; 28(7):707-10. PubMed ID: 10431429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
    Weber MA; Julius S; Kjeldsen SE; Jia Y; Brunner HR; Zappe DH; Hua TA; McInnes GT; Schork A; Mancia G; Zanchetti A
    J Hypertens; 2012 Nov; 30(11):2213-22. PubMed ID: 23011525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
    J Hypertens; 1998 Feb; 16(2):127-37. PubMed ID: 9535138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
    Jamerson KA; Bakris GL; Wun CC; Dahlöf B; Lefkowitz M; Manfreda S; Pitt B; Velazquez EJ; Weber MA
    Am J Hypertens; 2004 Sep; 17(9):793-801. PubMed ID: 15363822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.